These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33044358)

  • 41. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
    Del Sant LC; Sarin LM; Magalhães EJM; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda ALT; de Jesus Mari J
    J Psychopharmacol; 2020 Oct; 34(10):1155-1162. PubMed ID: 32638662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder.
    Sterpenich V; Vidal S; Hofmeister J; Michalopoulos G; Bancila V; Warrot D; Dayer A; Desseilles M; Aubry JM; Kosel M; Schwartz S; Vutskits L
    Anesthesiology; 2019 Jun; 130(6):923-935. PubMed ID: 31021848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.
    Albott CS; Shiroma PR; Cullen KR; Johns B; Thuras P; Wels J; Lim KO
    J Clin Psychiatry; 2017 Mar; 78(3):e308-e309. PubMed ID: 28394513
    [No Abstract]   [Full Text] [Related]  

  • 47. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
    Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
    JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we confidently use ketamine as a clinical treatment for depression?
    Loo C
    Lancet Psychiatry; 2018 Jan; 5(1):11-12. PubMed ID: 29277196
    [No Abstract]   [Full Text] [Related]  

  • 49. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.
    Altinay M; Karne H; Anand A
    Psychopharmacol Bull; 2019 Feb; 49(1):8-16. PubMed ID: 30858635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine.
    Chang L; Zhang K; Pu Y; Qu Y; Wang SM; Xiong Z; Ren Q; Dong C; Fujita Y; Hashimoto K
    Pharmacol Biochem Behav; 2019 Jun; 181():53-59. PubMed ID: 31034852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 55. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association between depression subtypes and response to repeated-dose intravenous ketamine.
    Wang C; Zhou Y; Zheng W; Liu W; Zhan Y; Li H; Chen L; Zhang B; Walter M; Li M; Li MD; Ning Y
    Acta Psychiatr Scand; 2019 Nov; 140(5):446-457. PubMed ID: 31483855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
    Hartberg J; Garrett-Walcott S; De Gioannis A
    Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression.
    Zhong X; He H; Zhang C; Wang Z; Jiang M; Li Q; Zhang M; Huang X
    J Affect Disord; 2016 Sep; 201():124-30. PubMed ID: 27208499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.